NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
19 Jan 2021

Hospital Vall d’Hebron Investigators Publish Early Data on Anaconda Biomed’s Mechanical Thrombectomy System for Ischemic Stroke

Initial single-center clinical study data supporting Anaconda Biomed’s Advanced Neurovascular Access™ (ANA) Catheter System for the treatment of ischemic stroke have been published
AM-Pharma Announces Enrollment and Financing of COVID-19 Cohort in Phase III REVIVAL Trial<
07 Jan 2021

AM-Pharma Announces Enrollment and Financing of COVID-19 Cohort in Phase III REVIVAL Trial

First patients with COVID-19 enrolled in the REVIVAL Phase III study
06 Jan 2021

CorWave Raises €35 Million in Series C Funding for Its Breakthrough Heart Pump; EIC Fund Joins as New Investor

CorWave raises 35 million euros to fund the next stages of its development, with the ambition to become a world-class medtech company serving heart failure patients.
Aura Biosciences Appoints David Johnson to Its Board of Directors<
05 Jan 2021

Aura Biosciences Appoints David Johnson to Its Board of Directors

Mr. Johnson is a biopharmaceutical business leader with more than 25 years of experience in drug development.
International Consortium Awarded Eurostars Grant for the Development of First-in-class Treatment of Metastatic Cancer<
16 Dec 2020

International Consortium Awarded Eurostars Grant for the Development of First-in-class Treatment of Metastatic Cancer

ONA Therapeutics will take the lead in the LIPOLOGIC program.
15 Dec 2020

Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia

Minoryx Therapeutics today announces topline results from the Phase 2 FRAMES clinical trial.
Splice Bio announces research funding by Cystic Fibrosis Foundation to develop novel AAV vectors<
10 Dec 2020

Splice Bio announces research funding by Cystic Fibrosis Foundation to develop novel AAV vectors

The Company will receive up to $343,000 in research funding.
19 Nov 2020

CorWave Secures a €500,000 Grant From the Paris Region for Its Industrial Facilities

CorWave has won the call for projects “Industry Stimulus Plan” operated by the Paris Region.
18 Nov 2020

Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease

Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has cleared Vivet’s Investigational New Drug (IND) application for the GATEWAY study.
16 Nov 2020

Minoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease Journal

Preclinical data highlights potential therapeutic action and protection against neurodegeneration.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка